Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of TLL018 in Chronic Spontaneous Urticaria
NCT05373355Phase 1Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of girocitinib in chronic spontaneous urticaria (CSU) (3 arms), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoints: Treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs, Blood pressure, pulse rate, respiratory rate, temperature and 3 more. Started May 2022; status: completed.
02
Drugs
girocitinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05373355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373355.